EXTH-74. IND-ENABLING CHARACTERIZATION OF DUAL DRD2- AND ClpP-TARGETING AGENT ONC206 AS THE NEXT IMIPRIDONE FOR CLINICAL NEURO-ONCOLOGY

ONC201 is the first bitopic antagonist of dopamine receptor D2 (DRD2) and allosteric mitochondrial protease ClpP agonist, that is well tolerated and induces durable tumor regressions in H3 K27M-mutant glioma patients. ONC206, a derivative of ONC201, is also a bitopic DRD2 antagonist that exhibits en...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Prabhu, Varun, Morrow, Sara, Kawakibi, Abed Rahman, Jitkova, Yulia, Jung, Jinkyu, Madhukar, Neel, Garnett, Mathew, McDermott, Ultan, Benes, Cyril, Wechsler-Reya, Robert, Elemento, Olivier, DeMorrow, Sharon, Schimmer, Aaron, Stogniew, Martin, Theeler, Brett, Gilbert, Mark, Allen, Joshua
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Preclinical Experimental Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650984/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.428
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares